MONITORING HUMAN EXPOSURE TO AFLATOXINS IN THE GAMBIA

黄曲霉毒素B1(AFB1)是最有效的肝脏之一 为实验动物所知的致癌物质。这种化学物质也是 由于霉菌在环境中的存在与 食品和商品的变质。这些食物的消耗量 导致许多地区的人们摄入高水平的黄曲霉毒素 亚洲和非洲的。许多研究人员使用了经典 用流行病学方法检查可能的因果关系 饮食中的黄曲霉毒素B与肝癌之间的关系。虽然很强 AFB1暴露与肝癌之间的关系一直是 发现，新技术直到最近才出现 监测黄曲霉毒素B1在人体内的暴露和代谢 人民。这些方法将有助于对角色的剖析 来自黄曲霉毒素的病毒制剂，如乙肝 肝癌的病因学。生物标志物的研究进展 评估接触黄曲霉毒素将有助于努力限制 人类群体中的潜在风险。在以下建议中 研究中，我们将同时检查季节和年度变化 黄曲霉毒素摄入、代谢、尿白蛋白处置 生活在冈比亚、西非的人有很高的患病风险 患上肝癌。 这些研究将系统地探索两者之间的对应关系 黄曲霉毒素的饮食摄入量与生物标记物，如 排泄的黄曲霉毒素-DNA加合物，尿中的氧化代谢产物，黄曲霉毒素 并将黄曲霉毒素共价结合到血清白蛋白上， 以确定这些标记物中哪些具有非侵入性 评估肝脏高危人群的暴露状况 癌症。

Aflatoxin Bl (AFBl) is one of the most potent liver carcinogens known for experimental animals. This chemical is also present in the environment as a result of mold related spoilage of foods and commodities. Consumption of these foods results in high intake of AFBl by people living in many regions of Asia and Africa. A number of researchers have used classic epidemiological methods to examine the possible causal relationship between AFBl in the diet and liver cancer. While strong associations between AFBl exposure and liver cancer have been found, new technologies have only recently become available to monitor individual exposure and metabolism of aflatoxin Bl in people. These methods will facilitate the dissection of the role of viral agents, such as hepatitis B, from aflatoxins in the etiology of liver cancer. The development of biomarkers to assess the exposure to aflatoxin will help in efforts to limit the potential risk in human populations. In the following proposed study we will examine both seasonal and annual variabilities in aflatoxin intake, metabolism, urinary and albumin disposition in people living in the Gambia, West Africa who are at high risk to develop liver cancer. These studies will systematically probe the correspondence between dietary intake of aflatoxins with biological markers, such as excreted AFB-DNA adducts, oxidative metabolites in urine, aflatoxin Ml in human milk and covalently bound aflatoxin to serum albumin, to determine which of these markers have utility for non-invasively assessing the exposure status of people at high risk for liver cancer.